stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
BioCryst Pharmaceuticals, Inc. (BCRX) Operating margin
BioCryst Pharmaceuticals, Inc.'s operating margin over the twelve months to 30 September 2026 was −30.1%, down 69.1 percentage points from fiscal 2025 (39.0%). Over the past ten years it has ranged from −981.1% (fiscal 2020) to 39.0% (fiscal 2025) — the current reading is the highest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of 0.00% and below the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | 39.0% | 39.54 |
| FY2024 | −0.56% | 30.73 |
| FY2023 | −31.3% | 23.52 |
| FY2022 | −54.8% | 58.27 |
| FY2021 | −113.1% | 868.04 |
| FY2020 | −981.1% | (777.46) |
| FY2019 | −203.7% | 252.54 |
| FY2018 | −456.2% | (228.25) |
| FY2017 | −228.0% | (43.50) |
| FY2016 | −184.5% | (102.71) |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | 29.6% | (15.54) |
| Jun 2026 | 45.1% | 493.67 |
| Mar 2026 | −448.6% | (512.60) |
| Dec 2025 | 64.1% | 45.49 |
| 43 more quarters | Free account |
Against its own ten years
Operating margin against peers
| Company | Operating margin |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | 25.0% |
| ANIP ANI Pharmaceuticals, Inc. compare | 16.0% |
| XERS Xeris Biopharma Holdings, Inc. compare | 12.7% |
| TRLV Trulieve Cannabis Corp. compare | 0.00% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| BCRX BioCryst Pharmaceuticals, Inc. | −30.1% |
| PRGO Perrigo Company plc compare | −39.4% |
| ALVO Alvotech compare | −42.4% |
| RGC Regencell Bioscience Holdings Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on BCRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement